Soleno Therapeutics, Inc. Series A Warrant
SLNOW
SLNOW was delisted on the 8th of November, 2019.
3 hedge funds and large institutions have $29K invested in Soleno Therapeutics, Inc. Series A Warrant in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
40% less funds holding
Funds holding: 5 → 3 (-2)
77% less capital invested
Capital invested by funds: $124K → $29K (-$95K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$4K |
| 2 |
VF
Virtu Financial
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $27K | – | – | – |
|
2
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$4K | -6,000 | Closed |
|
|
VF
4
Virtu Financial
New York
| – | -$1K | -2,503 | Closed |
|
SLNOW Hedge Fund Activity: Q4 2017 in Review
3 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics, Inc. Series A Warrant (SLNOW) for Q4 2017, worth a combined $29K — down 77% from $124K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SLNOW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $4K sold.
- 3 institutional investors held Soleno Therapeutics, Inc. Series A Warrant (SLNOW) as of Q4 2017, down from 5 in Q3 2017.
- Funds reported $29K of Soleno Therapeutics, Inc. Series A Warrant stock for Q4 2017, down 77% quarter-over-quarter.
- 0 funds opened new Soleno Therapeutics, Inc. Series A Warrant positions in Q4 2017 and 2 closed out, a net change of -2 holders.
- The largest Soleno Therapeutics, Inc. Series A Warrant seller in Q4 2017 was Hudson Bay Capital Management, an estimated $4K sold.
Based on aggregated 13F filings for Q4 2017.